AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02112097 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PASI 75 n(%) subdermally at Week 36
Description: PASI 75 n(%) as Efficacy of Enbrel subdermally at Week 36, in terms of the proportion of patients who achieved a reduction in score of at least 75% from baseline by the PASI.
Study NCT02112097 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adverse Reactions of Enbrel subcutaneously
Description: Adverse Reactions of Enbrel subcutaneously at Week 36, in number of Injection site reactions, Heart failure, Allergic Reactions, Blood problems/low blood counts, Nervous system, Infections, Malignancies, Immunogenicity, and Autoantibodies.
Study NCT01371006 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: normal dose
Description: efavirenz once daily
Study NCT01371006 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: low dose
Description: Efavirenz single dosing once daily
Study NCT02804191 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LO2A
Description: eye drop solution.
Study NCT02804191 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Placebo
Study NCT00448110 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous Diclofenac (DIC075V)
Description: Intravenous Diclofenac (DIC075V): 1 of 2 dosage levels
Study NCT00448110 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous Ketorolac
Description: Intravenous Ketorolac
Study NCT00448110 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo
Study NCT01265875 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Human Secretin
Description: Dose Escalation
Study NCT02112097 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adverse Reactions of Enbrel subdermally at Week 36
Description: Adverse Reactions of Enbrel subdermally at Week 36, in number of Injection site reactions, Heart failure, Allergic Reactions, Blood problems/low blood counts, Nervous system, Infections, Malignancies, Immunogenicity, and Autoantibodies.
Study NCT02112097 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gadolinium
Description: For Right Upper Arm Total Persistent % subdermally, on MRI at 6 hrs, 12 hrs, and 24 hrs.~Gadolinium Magnevist® (gadopentetate dimeglumine) .1cc/ diluted with .9cc normal saline subcutaneously for 30 patients, and subdermally with ASIS Device for 30 patients.
Study NCT02112097 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gadolinium
Description: For Right Upper Arm Total Persistent % subcutaneously, on MRI at 6 hrs, 12 hrs, and 24 hrs.~Gadolinium Magnevist® (gadopentetate dimeglumine) .1cc/ diluted with .9cc normal saline subcutaneously for 30 patients, and subdermally with ASIS Device for 30 patients.
Study NCT02112097 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gadolinium
Description: For Right Upper Arm Relative Prolongation Ability Score or total Persistent % of Gadolinium subdermally over total Persistent % of Gadolinium subcutaneously on MRI.
Study NCT02501330 — intervention group
Intervention type: DRUG
Intervention: Bosutinib
Description: The recommended adult dose of bosutinib is 500 mg orally once daily with food. For newly-diagnosed chronic phase CML, the recommended dose is 400 mg. The dose may be adjusted appropriately according to the patient's condition; however, the maximum dose is 600 mg once daily.
Study NCT01268644 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leptin
Description: weight based sub-cutaneous injection twice daily of Leptin
Study NCT03891082 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: B-Lynch
Description: A 70 mm round bodied hand needle on which a No. 2 absorbable suture is mounted is used to puncture the uterus 3 cm from the right lower edge of the uterine incision and 3 cm from the right lateral border. The mounted No. 2 absorbable suture is threaded through the uterine cavity to emerge at the upper incision margin 3 cm above and approximately 4 cm from the lateral border
Study NCT03891082 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: BALLOON INSERTION
Description: Insert the balloon portion of the catheter in the uterus; making certain that the entire balloon is inserted past the cervical canal and internal ostium. NOTE: Avoid excessive force when inserting the balloon into the uterus. Place a Foley catheter in patient bladder to collect and monitor urine output. To ensure maintenance of correct placement and maximize tamponade effect, the vaginal canal may be packed with iodine or antibiotic soaked vaginal gauze at this time.
Study NCT02489981 — intervention group
Intervention type: DRUG
Intervention: Spiriva
Description: 60 puffs
Study NCT01241448 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered Orally
Study NCT03430609 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic treatment for endometrioma Astus©
Description: Laparoscopic surgery will be performed by the same surgeon, according to the routine of the service.In all of the groups, endometrioma will be removed by means of the traction and countertraction techniques. Adhesiolysis will be performed to separate the ovary from the adjacent structures as needed. In case of cyst rupture, the contents will be aspirated, and the site where the endometrioma contents fell will be exhaustively rinsed. In the hemostasis , the investigators will use coagulation with bipolar tweezers Astus Medical© in this group.
Study NCT03430609 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: AMH Level
Description: The AMH levels will be quantitatively measured via ELISA, Enzyme-Linked Immunosorbent Assay (Diagnostic Systems Laboratories, Webster, TX), with a detection sensitivity of 0.006 ng/mL.~The participants' sera will be obtained from blood samples after centrifugation for 10 minutes to separate the cell contents and debris. Each serum sample will be transferred to polypropylene tubes and stored at -70ºC. Venous blood samples will be collected before surgery (on the day ultrasound is performed for antral follicle count, approximately 1 month before surgery) and 1, 3 and 6 months after surgery.
Study NCT02861729 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vita Suprinity
Description: zirconia reinforced lithium silicate partial coverage restorations
Study NCT02861729 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: IPS e.max
Description: lithium disilicate partial coverage restorations
Study NCT02475161 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-42847922
Description: JNJ-42847922 will be administered as 20 mg tablet orally.
Study NCT02475161 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rabeprazole
Description: Rabeprazole will be administered as 20 mg tablet orally.
Study NCT00888472 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Leukocytapheresis
Description: 5000 ml, the blood volume per body, treated once. Twice at an interval of 6 days.
Study NCT01301378 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Molteno 3 glaucoma drainage shunt
Description: Patients needing glaucoma drainage surgery
Study NCT00960687 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fenofibric Acid (Fibricor™) 105 mg Tablet
Description: 1 x 105 mg fenofibric acid (Fibricor™) tablet administered 30 minutes after the initiation of a standard breakfast.
Study NCT00960687 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fenofibrate (Tricor®) 145 mg Tablet
Description: 1 x 145 mg Fenofibrate (Tricor®) tablet administered 30 minutes after the start of a standard breakfast.
Study NCT01615757 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ara-c
Description: IV formulation, administered as a 2 hr infusion in 1 pint of normal saline, BD on D1,3,5 at 3 gm/m2 /dose
Study NCT01615757 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ara-c
Description: IV formulation, administered as a 2 hr infusion in 1 pint of normal saline, BD on D1,3,5 at 2 gm/m2 /dose
Study NCT00929201 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sitagliptin phosphate/metformin hydrochloride FDC
Description: Single dose sitagliptin/metformin 50/500 mg FDC tablet after consumption of a high-fat meal in one of two treatment periods.
Study NCT00929201 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sitagliptin phosphate
Description: Single dose sitagliptin 50 mg tablet after consumption of a high-fat meal in one of two treatment periods.
Study NCT00929201 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin hydrochloride
Description: Single dose metformin 500 mg tablet after consumption of a high-fat meal in one of two treatment periods.
Study NCT03256526 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0 mg
Study NCT03256526 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06835919 Low Dose
Description: 75 mg once daily
Study NCT03256526 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06835919 High Dose
Description: 300 mg once daily
Study NCT03971032 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Infrared Spectroscopy
Description: This device uses spectral absorption of the tissue taken during hysteroscopy to determine immediate diagnosis of malignancy
Study NCT00958828 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Nelfilcon A contact lens
Description: Spherical, soft contact lens for daily disposable wear
Study NCT00958828 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Narafilcon A contact lens
Description: Spherical, soft contact lens for daily disposable wear
Study NCT02024386 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Riociguat
Description: After completion of first V02 max test at altitude, subjects will have a 3-hour rest period. Riociguat will be administered at the 90-minute mark of this rest period.
Study NCT04338646 — intervention group
Intervention type: OTHER
Intervention: Clinical tests
Description: Questionnaire about urinary symptoms, gait difficulties, fear of falling. Clinical test: Time to be Ready to Void
Study NCT03107416 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hepatic artery embolization (HAE)
Description: The intervention being studied is HAE for the treatment of HCC in combination with Bumetanide. HAE is a standard of care procedure.
Study NCT03107416 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bumetanide
Description: Intra-arterial (IA) injection of 0.01mg/kg of Bumetanide in the first cohort, 0.02 mg/kg in the second cohort and 0.04 mg/kg of IA Bumetanide in the final cohort patients during standard HAE until stasis is evident.
Study NCT03586986 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Brain MRI
Description: Perform brain MRI; draw blood; fill out bioscreen questionnaire; perform SDMT
Study NCT01966107 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aclidinium Bromide
Description: 400 μg, twice per day, oral administration via a multi-dose dry-powder inhaler (DPI)
Study NCT01966107 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Dose matched placebo, twice per day, oral administration via a multi-dose dry-powder inhaler (DPI)
Study NCT02856282 — intervention group
Intervention type: DRUG
Intervention: Pirinase Hayfever Relief for Adults 0.05% Nasal Spray
Description: Aqueous suspension of 0.05% micronised fluticasone propionate.Each actuation contains 50 micrograms of fluticasone propionate
Study NCT03300882 — intervention group
Intervention type: OTHER
Intervention: Procedure
Description: Serial blood draws. Participants will be enrolled either pre-transplant or within 45 days post-transplant and will be followed over the course of 18 months post transplant. Protocol mandated serial measurement of cytomegalovirus (CMV)-specific immune signature will occur pre-transplant (as applicable) and at post-transplant timepoint months 2, -3, -6, -9, -12 and -18.
Study NCT03285347 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Computer-based cognitive training
Description: Computer-based cognitive programmes are computer programmes designed as games with the aim of training patients in certain cognitive domains.
Study NCT02863796 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: WhiteSwell System
Description: To promote movement of interstitial fluid to the intravascular space to allow for the body to remove it, in conjunction with a diuresis regimen.
Study NCT03268083 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: EV71 vaccine ([0.5 μg total protein + adjuvant 150 μg AI(OH)3] per dose)
Description: Two vaccinations at 28 days apart
Study NCT01495962 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Botulinum Toxin Type A
Description: Six 25 cc injection of Botulinum Toxin A
Study NCT01495962 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (Normal Saline)
Study NCT03268083 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: EV71 vaccine ([1 μg total protein + adjuvant 150 μg AI(OH)3] per dose)
Description: Two vaccinations at 28 days apart
Study NCT03268083 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: EV71 vaccine ([1 μg total protein ] per dose)
Description: Two vaccinations at 28 days apart
Study NCT03765489 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: electrical muscle stimulation
Description: electrical muscle stimulation: The parameters used in biceps were: 35 Hz, 250 μs and in quadriceps were: 50 Hz, 400 μs. In both, biphasic wave was used, 45 minutes of total work, 5 seconds of contraction and 10 seconds of relaxation and the intensity was adjusted to present a visible contraction
Study NCT03765489 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: conventional physical therapy
Description: conventional physical therapy according to the adaptation of the Start to move protocol of Gosselink et al
Study NCT03765489 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: conventional physical therapy
Description: conventional physical therapy according to the adaptation of the Start to move protocol of Gosselink et al
Study NCT03359148 — intervention group
Intervention type: DEVICE
Intervention: Disposable ventilator system
Study NCT03359148 — intervention group
Intervention type: DEVICE
Intervention: Conventional reused ventilator system
Study NCT04456777 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vortioxetine
Description: vortioxetine will be administreted for 3 months
Study NCT04456777 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vortioxetine
Description: vortioxetine will be administreted for 3 months
Study NCT00837837 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chlorpheniramine
Study NCT02673177 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: robot-assisted total mesorectal excision
Description: The Da Vinci Surgical System may help to protect subtle anatomical structure and provide more functional protection when compared to laparoscopic surgery. This study aimed to compare RTME and laparoscopic total mesorectal excision (LTME) for rectal cancer with regard to Urinary, sexual function and sphincter- preservation outcomes.
Study NCT02673177 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: laparoscopic total mesorectal excision
Description: Traditional laparoscopic total mesorectal excision (LTME) for rectal cancer.
Study NCT02437773 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Behavioral Therapy - Adolescents
Description: A therapy which gradually yet repeatedly exposes adolescent patients to their obsessive compulsive-relevant error cues during a task performance until their anxiety habituates.
Study NCT02437773 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Stress Management Therapy - Adolescents
Description: An active control therapy with minimal effects on OCD symptoms.
Study NCT02437773 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Optional CBT - Adolescents
Description: This is the cross-over element for those that completed the SMT treatment group and opt to have the OCD treatment.
Study NCT02437773 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Behavioral Therapy - Adults
Description: A therapy which gradually yet repeatedly exposes adult patients to their obsessive compulsive-relevant error cues during a task performance until their anxiety habituates.
Study NCT02437773 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Stress Management Therapy - Adults
Description: An active control therapy with minimal effects on OCD symptoms.
Study NCT02437773 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Optional CBT - Adults
Description: This is the cross-over element for those that completed the SMT treatment group and opt to have the OCD treatment.
Study NCT02437773 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: fMRI only - Healthy Control Adults
Description: Two fMRI's only, scheduled at 12-weeks apart. This is for Healthy Control Adults and is used only as a means for observation, NOT as an intervention to be studied.
Study NCT02437773 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: fMRI only - Healthy Control Adolescents
Description: Two fMRI's only, scheduled at 12-weeks apart. This is for Healthy Control Adolescents and is used only as a means for observation, NOT as an intervention to be studied.
Study NCT00799890 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sunphenon EGCG
Description: 200-800mg (1-4 capsules)
Study NCT00799890 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1-4 capsules
Study NCT01240759 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-707106 Dose A
Description: One S-707106 A tablet
Study NCT01240759 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-707106 Dose B
Description: One S-707106 B tablet
Study NCT01240759 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-707106 Dose C
Description: Four S-707106 4 X B tablets
Study NCT01240759 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo A tablet
Description: Up to 4 Placebo A tablets
Study NCT01240759 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo A tablet
Description: Up to 4 Placebo A tablets
Study NCT01240759 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: The standard of care dose of metformin for each patient
Study NCT01240759 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: The standard of care dose of metformin for each patient
Study NCT01004354 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ergocalciferols
Description: 2000 international units by mouth daily for 8 weeks.
Study NCT01198470 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TRIUMPH® Lumbar Artificial Disc
Description: The TRIUMPH® Lumbar Artificial Disc is an articulating artificial disc inserted using a posterolateral approach to the lumbar spine.
Study NCT02845024 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxycycline Group
Description: Oral doxycycline 100mg was taken within 15 days
Study NCT02845024 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo Group
Description: Oral placebo was taken within 15 days
Study NCT02913911 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: feedback
Description: Sit to stand training with external feedback
Study NCT02913911 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: feedback
Description: Sit to stand training with external feedback
Study NCT00697463 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Teriparatide (PTH 1-34)
Description: 20 micrograms subcutaneous injection daily
Study NCT02100462 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chlorthalidone 12.5 mg
Study NCT02100462 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide 25 mg
Study NCT02100462 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin 81 mg
Study NCT03718988 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Meat products
Description: Traditional meat products (beef burger patties, pork sausage, etc.)
Study NCT03718988 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Plant Alternative products
Description: Plant-based alternatives (The Beyond Burger, Beyond Sausage, etc.)
Study NCT03045263 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Pivotal Response Treatment
Description: Behavioral intervention for autism
Study NCT03494712 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S 95010
Description: Single administration of S 95010 in healthy volunteers
Study NCT03494712 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single administration of placebo in healthy volunteers
Study NCT01268670 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen
Description: Subjects will receive topical LET and oral ibuprofen.
Study NCT01268670 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxycodone
Description: Subjects will receive topical LET and oral oxycodone.
Study NCT01268670 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will receive topical LET and oral placebo.